Clinical trials: Placenta Previa Bleeding, open to volunteers
Placenta Previa
Tranexamic Acid vs Vasopressin in Placenta Previa Trial
Placenta previa is a major obstetric condition associated with increased risk of excessive blood loss during cesarean section, leading to maternal morbidity and mortality.
- Trial name
- TXA-VASO-PP (NCT07423156)
- Testing
- Group A: Tranexamic acid, Group B: Vasopressin
- Where
- Pakistan
- Volunteers
- 58 people
- Sponsor
- Allama Iqbal Medical College
Placenta Previa, Placenta Accreta Spectrum
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta.
- Conditions
- Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
- Trial name
- NCT07025954
- Testing
- Cesarean delivery
- Where
- 6 sites in China
- Volunteers
- 600 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Postpartum Hemorrhage
TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA
Several randomized, controlled trials, mostly involving women undergoing cesarean delivery, have shown that the prophylactic intravenous administration of 1 g of tranexamic acid after childbirth reduced blood loss.
- Trial name
- TRAAPrevia (NCT04304625)
- Testing
- Tranexamic Acid / Sodium chloride
- Where
- France
- Volunteers
- 1,380 people
- Sponsor
- University Hospital, Bordeaux
Placenta Previa
Effect of a Cervical Pessary on the Rate of Bleeding in Placenta Praevia
This study evaluates whether use of a cervical pessary can reduce vaginal bleeding and prolong pregnancy in women with placenta previa or a low-lying placenta.
- Trial name
- NCT07667777
- Testing
- Cervical pessary
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- Asklepios proresearch